Detalhe da pesquisa
1.
PBSC mobilization in lymphoma patients: analysis of risk factors for collection failure and development of a predictive score based on the kinetics of circulating CD34+ cells and WBC after chemotherapy and G-CSF mobilization.
Hematol Oncol
; 33(3): 125-32, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24890497
2.
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Am J Hematol
; 89(2): 119-24, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24122886
3.
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
Haematologica
; 98(2): 239-46, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23065521
4.
Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study.
J Clin Oncol
; 41(19): 3523-3533, 2023 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37071836
5.
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older.
J Clin Oncol
; 39(11): 1203-1213, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33444079
6.
Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available.
Leuk Lymphoma
; 60(14): 3493-3502, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31359808
7.
Changes in multiple myeloma epidemiology in the last thirty years: a single centre experience.
Eur J Cancer
; 42(3): 396-402, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16403623
8.
Efficacy and safety of fotemustine for the treatment of relapsed and refractory multiple myeloma patients.
Eur J Haematol
; 82(3): 240-1, 2009 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-19018860
9.
WT1 overexpression at diagnosis may predict favorable outcome in patients with de novo non-M3 acute myeloid leukemia.
Leuk Lymphoma
; 52(10): 1961-9, 2011 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21942328
10.
Changing pattern of presentation in monoclonal gammopathy of undetermined significance: a single-center experience with 1400 patients.
Medicine (Baltimore)
; 89(4): 211-216, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20616660
11.
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Leuk Lymphoma
; 51(2): 275-8, 2010 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20038234
12.
Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia.
Leuk Lymphoma
; 53(7): 1409-11, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22233113
13.
A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
Leuk Res
; 33(4): 577-8, 2009 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18842298